Watch ARTV. Know when insiders buy.
One email the day a filing lands. Free.
Work order
28
FLAG · insiders 26, shorts 29
Insiders, 90 days
−$1M
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $547.1MP/E —DIV YIELD —FCF YIELD -14.06%REV TTM —NET INCOME −$90.8MNET CASH —52W 2.28 – 13.39SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$26.9M | −$25M | — | -0.63 | −$20.4M | $415K | −$20.8M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$24.4M | −$23.5M | — | -0.95 | −$20.9M | $242K | −$21.2M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$21.9M | −$20.8M | — | -0.84 | −$14.7M | $421K | −$15.1M | Mar 10 |
| Q3 2025 · Sep 30 | — | — | — | −$22.9M | −$21.5M | — | -0.88 | −$19.2M | $600K | −$19.8M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$22.8M | −$21.3M | — | -0.87 | −$23M | $1.1M | −$24M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$22.2M | −$20.3M | — | -0.83 | −$19.8M | $511K | −$20.4M | Aug 6 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$18.3M | −$16.1M | — | 1.35 | −$14.7M | $64K | −$14.7M | Mar 10 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$18.3M | −$17.5M | −254.9% | -0.92 | −$11.6M | $96K | −$11.7M | Nov 12 |
| Q2 2024 · Jun 30 | $0 | — | — | −$16.2M | −$17.8M | — | -22.00 | −$13.7M | $464K | −$14.1M | Nov 12 |
| Q1 2024 · Mar 31 | $251K | — | — | −$14.5M | −$14M | — | -17.24 | −$15.1M | $18K | −$15.1M | Nov 12 |
| Q4 2023 · Dec 31derived | $2.4M | — | — | −$12M | −$12M | — | -14.89 | −$10.7M | $636K | −$11.3M | Mar 24 |
| Q3 2023 · Sep 30 | $26.7M | — | — | $10.8M | $11.3M | — | 1.62 | −$10.7M | $179K | −$10.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$89.8M | −$83.9M | — | -3.43 | −$76.8M | $2.6M | −$79.3M | — | — |
| FY2024 · to Dec 31 | $251K | — | −$67.3M | −$65.4M | -26045.0% | -5.81 | −$55M | $642K | −$55.7M | — | — |
| FY2023 · to Dec 31 | $33.5M | — | −$30.7M | −$28.7M | -85.8% | -35.78 | −$47.4M | $3.3M | −$50.7M | — | — |
Every number comes from Artiva Biotherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.